Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Bullish +65

Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings

📉 Novo Nordisk (NVO) stock has dropped more than 30% since mid-2024, extending an ongoing downtrend.

📅 The company is set to report Q2 earnings results next week with a focus on transformation plans.

💊 Oral Wegovy is gaining prescriptions rapidly and expanding the addressable market for new GLP-1 patients.

🌍 International approvals and a prospective China filing could accelerate oral Wegovy expansion in H2 2026.

🚀 A potential CagriSema regulatory filing offers a major catalyst with commercialization expected in 2027.

💰 Successful CagriSema launch could materially improve growth expectations and valuation multiples.

Bullish Signals
  • Oral Wegovy is rapidly gaining prescriptions and attracting predominantly new GLP-1 patients without materially cannibalizing established treatments.
  • Approvals across international markets and a prospective China filing are poised to accelerate oral Wegovy's expansion during the second half of 2026.
  • A potential CagriSema regulatory filing provides a major catalyst, as successful commercialization in 2027 could materially improve growth expectations and valuation multiples.
  • The author maintains a bullish stance on NVO despite the recent stock decline.
Full Analysis
Novo Nordisk (NVO) stock has declined over 30% since mid-2024, continuing a downtrend that analysts view as a potential generational buying opportunity ahead of the company's upcoming Q2 earnings report. Investors are shifting their focus from immediate quarterly beats to management's confidence in executing long-term transformation plans. The article highlights strong momentum for oral Wegovy, which is rapidly gaining prescriptions and attracting new GLP-1 patients without significantly cannibalizing existing treatments. Approvals in international markets and a prospective filing in China are expected to accelerate the expansion of this product line during the second half of 2026. A major catalyst identified is the potential regulatory filing for CagriSema, a next-generation drug. Successful commercialization of CagriSema in 2027 could materially improve growth expectations and boost Novo Nordisk's valuation multiple, reinforcing the bullish outlook despite recent price declines.